Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infigratinib - Helsinn/QED Therapeutics

Drug Profile

Infigratinib - Helsinn/QED Therapeutics

Alternative Names: BBP-831; BGJ-398; BGJ-398 phosphate; Infigratinib phosphate; NVP-BGJ398; TRUSELTIQ

Latest Information Update: 07 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Array BioPharma; Helsinn; LianBio; Novartis; Novartis Oncology; QED Therapeutics
  • Class Aniline compounds; Antineoplastics; Chlorobenzenes; Methylurea compounds; Phenyl ethers; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cholangiocarcinoma
  • Phase III Bladder cancer; Urogenital cancer
  • Phase II Achondroplasia; Gastric cancer; Head and neck cancer; Oesophageal cancer
  • Phase I/II Solid tumours
  • Phase I Breast cancer
  • Phase 0 Glioblastoma
  • Discontinued Haematological malignancies; Malignant melanoma

Most Recent Events

  • 03 Nov 2022 BridgeBio Pharma plans pivotal phase III trial in Achondroplasia in 2023
  • 12 Aug 2022 BridgeBio Pharma filed patent applications to provide market protection as late as 2041
  • 10 Aug 2022 QED Therapeutics withdrawn a phase-I BLASST-3 trial in Bladder cancer (Neoadjuvant therapy) in USA (PO) prior enrolment due to low accrual (NCT04972253)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top